Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1994 Jun;70(824):404–410. doi: 10.1136/pgmj.70.824.404

Multiple myeloma: current treatment.

D Samson 1
PMCID: PMC2397727  PMID: 7518081

Full text

PDF
404

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexanian R., Barlogie B., Gutterman J. Alpha-interferon combination therapy of resistant myeloma. Am J Clin Oncol. 1991 Jun;14(3):188–192. doi: 10.1097/00000421-199106000-00003. [DOI] [PubMed] [Google Scholar]
  2. Alexanian R., Bonnet J., Gehan E., Haut A., Hewlett J., Lane M., Monto R., Wilson H. Combination chemotherapy for multiple myeloma. Cancer. 1972 Aug;30(2):382–389. doi: 10.1002/1097-0142(197208)30:2<382::aid-cncr2820300213>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  3. Alexanian R., Yap B. S., Bodey G. P. Prednisone pulse therapy for refractory myeloma. Blood. 1983 Sep;62(3):572–577. [PubMed] [Google Scholar]
  4. Anderson K. C., Barut B. A., Ritz J., Freedman A. S., Takvorian T., Rabinowe S. N., Soiffer R., Heflin L., Coral F., Dear K. Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. Blood. 1991 Feb 15;77(4):712–720. [PubMed] [Google Scholar]
  5. Barlogie B., Gahrton G. Bone marrow transplantation in multiple myeloma. Bone Marrow Transplant. 1991 Feb;7(2):71–79. [PubMed] [Google Scholar]
  6. Barlogie B., Smith L., Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984 May 24;310(21):1353–1356. doi: 10.1056/NEJM198405243102104. [DOI] [PubMed] [Google Scholar]
  7. Barlogie B., Velasquez W. S., Alexanian R., Cabanillas F. Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma. J Clin Oncol. 1989 Oct;7(10):1514–1517. doi: 10.1200/JCO.1989.7.10.1514. [DOI] [PubMed] [Google Scholar]
  8. Bensinger W. I., Buckner C. D., Clift R. A., Petersen F. B., Bianco J. A., Singer J. W., Appelbaum F. R., Dalton W., Beatty P., Fefer A. Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. J Clin Oncol. 1992 Sep;10(9):1492–1497. doi: 10.1200/JCO.1992.10.9.1492. [DOI] [PubMed] [Google Scholar]
  9. Billadeau D., Quam L., Thomas W., Kay N., Greipp P., Kyle R., Oken M. M., Van Ness B. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood. 1992 Oct 1;80(7):1818–1824. [PubMed] [Google Scholar]
  10. Bird J. M., Russell N. H., Samson D. Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence for cure in long-term survivors. Bone Marrow Transplant. 1993 Dec;12(6):651–654. [PubMed] [Google Scholar]
  11. Case D. C., Jr, Lee D. J., 3rd, Clarkson B. D. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am J Med. 1977 Dec;63(6):897–903. doi: 10.1016/0002-9343(77)90543-5. [DOI] [PubMed] [Google Scholar]
  12. Cooper M. R., Dear K., McIntyre O. R., Ozer H., Ellerton J., Canellos G., Bernhardt B., Duggan D., Faragher D., Schiffer C. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. J Clin Oncol. 1993 Jan;11(1):155–160. doi: 10.1200/JCO.1993.11.1.155. [DOI] [PubMed] [Google Scholar]
  13. Cuzick J., De Stavola B. L., Cooper E. H., Chapman C., MacLennan I. C. Long-term prognostic value of serum beta 2 microglobulin in myelomatosis. Br J Haematol. 1990 Aug;75(4):506–510. doi: 10.1111/j.1365-2141.1990.tb07790.x. [DOI] [PubMed] [Google Scholar]
  14. Dimopoulos M. A., Delasalle K. B., Champlin R., Alexanian R. Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma. Br J Haematol. 1993 Feb;83(2):240–244. doi: 10.1111/j.1365-2141.1993.tb08278.x. [DOI] [PubMed] [Google Scholar]
  15. Durie B. G., Dixon D. O., Carter S., Stephens R., Rivkin S., Bonnet J., Salmon S. E., Dabich L., Files J. C., Costanzi J. J. Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol. 1986 Aug;4(8):1227–1237. doi: 10.1200/JCO.1986.4.8.1227. [DOI] [PubMed] [Google Scholar]
  16. Fermand J. P., Chevret S., Levy Y., Miclea J. M., Tsapis A., Gerota J., Benbunan M., Brouet J. C. The role of autologous blood stem cells in support of high-dose therapy for multiple myeloma. Hematol Oncol Clin North Am. 1992 Apr;6(2):451–462. [PubMed] [Google Scholar]
  17. Gahrton G., Tura S., Ljungman P., Belanger C., Brandt L., Cavo M., Facon T., Granena A., Gore M., Gratwohl A. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med. 1991 Oct 31;325(18):1267–1273. doi: 10.1056/NEJM199110313251802. [DOI] [PubMed] [Google Scholar]
  18. Gore M. E., Selby P. J., Viner C., Clark P. I., Meldrum M., Millar B., Bell J., Maitland J. A., Milan S., Judson I. R. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet. 1989 Oct 14;2(8668):879–882. doi: 10.1016/s0140-6736(89)91548-1. [DOI] [PubMed] [Google Scholar]
  19. Gottlieb D. J., Prentice H. G., Heslop H. E., Bello-Fernandez C., Bianchi A. C., Galazka A. R., Brenner M. K. Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy. Blood. 1989 Nov 15;74(7):2335–2342. [PubMed] [Google Scholar]
  20. Gregory W. M., Richards M. A., Malpas J. S. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol. 1992 Feb;10(2):334–342. doi: 10.1200/JCO.1992.10.2.334. [DOI] [PubMed] [Google Scholar]
  21. Harousseau J. L., Milpied N., Laporte J. P., Collombat P., Facon T., Tigaud J. D., Casassus P., Guilhot F., Ifrah N., Gandhour C. Double-intensive therapy in high-risk multiple myeloma. Blood. 1992 Jun 1;79(11):2827–2833. [PubMed] [Google Scholar]
  22. Jaffe J. P., Bosch A., Raich P. C. Sequential hemi-body radiotherapy in advanced multiple myeloma. Cancer. 1979 Jan;43(1):124–128. doi: 10.1002/1097-0142(197901)43:1<124::aid-cncr2820430119>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  23. Klein B., Wijdenes J., Zhang X. G., Jourdan M., Boiron J. M., Brochier J., Liautard J., Merlin M., Clement C., Morel-Fournier B. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood. 1991 Sep 1;78(5):1198–1204. [PubMed] [Google Scholar]
  24. Klein B., Zhang X. G., Jourdan M., Boiron J. M., Portier M., Lu Z. Y., Wijdenes J., Brochier J., Bataille R. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur Cytokine Netw. 1990 Oct-Nov;1(4):193–201. [PubMed] [Google Scholar]
  25. Lahtinen R., Laakso M., Palva I., Virkkunen P., Elomaa I. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet. 1992 Oct 31;340(8827):1049–1052. doi: 10.1016/0140-6736(92)93075-x. [DOI] [PubMed] [Google Scholar]
  26. Ludwig H., Cohen A. M., Huber H., Nachbaur D., Jungi W. F., Senn H., Günczler P., Schüller J., Eckhardt S., Seewann H. L. Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results. Eur J Cancer. 1991;27 (Suppl 4):S40–S45. doi: 10.1016/0277-5379(91)90570-4. [DOI] [PubMed] [Google Scholar]
  27. Ludwig H., Fritz E., Kotzmann H., Höcker P., Gisslinger H., Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med. 1990 Jun 14;322(24):1693–1699. doi: 10.1056/NEJM199006143222402. [DOI] [PubMed] [Google Scholar]
  28. MacLennan I. C., Chapman C., Dunn J., Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. Lancet. 1992 Jan 25;339(8787):200–205. doi: 10.1016/0140-6736(92)90004-m. [DOI] [PubMed] [Google Scholar]
  29. Mandelli F., Avvisati G., Amadori S., Boccadoro M., Gernone A., Lauta V. M., Marmont F., Petrucci M. T., Tribalto M., Vegna M. L. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med. 1990 May 17;322(20):1430–1434. doi: 10.1056/NEJM199005173222005. [DOI] [PubMed] [Google Scholar]
  30. Montuoro A., De Rosa L., De Blasio A., Pacilli L., Petti N., De Laurenzi A. Alpha-2a-interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma. Br J Haematol. 1990 Nov;76(3):365–368. doi: 10.1111/j.1365-2141.1990.tb06369.x. [DOI] [PubMed] [Google Scholar]
  31. Osterborg A., Björkholm M., Björeman M., Brenning G., Carlson K., Celsing F., Gahrton G., Grimfors G., Gyllenhammar H., Hast R. Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. Blood. 1993 Mar 15;81(6):1428–1434. [PubMed] [Google Scholar]
  32. Peest D., Deicher H., Coldewey R., Leo R., Bartl R., Bartels H., Braun H. J., von Broen I. M., Fischer J. T., Gramatzki M. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatment Group. Onkologie. 1990 Dec;13(6):458–460. doi: 10.1159/000216820. [DOI] [PubMed] [Google Scholar]
  33. Reece D. E., Barnett M. J., Connors J. M., Klingemann H. G., O'Reilly S. E., Shepherd J. D., Sutherland H. J., Phillips G. L. Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide. Bone Marrow Transplant. 1993 Feb;11(2):139–146. [PubMed] [Google Scholar]
  34. Rostom A. Y., O'Cathail S. M., Folkes A. Systemic irradiation in multiple myeloma: a report on nineteen cases. Br J Haematol. 1984 Nov;58(3):423–431. doi: 10.1111/j.1365-2141.1984.tb03989.x. [DOI] [PubMed] [Google Scholar]
  35. Samson D., Gaminara E., Newland A., Van de Pette J., Kearney J., McCarthy D., Joyner M., Aston L., Mitchell T., Hamon M. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet. 1989 Oct 14;2(8668):882–885. doi: 10.1016/s0140-6736(89)91549-3. [DOI] [PubMed] [Google Scholar]
  36. Selby P., Zulian G., Forgeson G., Nandi A., Milan S., Meldrum M., Viner C., Osborne R., Malpas J. S., McElwain T. J. The development of high dose melphalan and of autologous bone marrow transplantation in the treatment of multiple myeloma: Royal Marsden and St Bartholomew's Hospital studies. Hematol Oncol. 1988 Apr-Jun;6(2):173–179. doi: 10.1002/hon.2900060218. [DOI] [PubMed] [Google Scholar]
  37. Sonneveld P., Durie B. G., Lokhorst H. M., Marie J. P., Solbu G., Suciu S., Zittoun R., Löwenberg B., Nooter K. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet. 1992 Aug 1;340(8814):255–259. doi: 10.1016/0140-6736(92)92353-h. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES